Clinical trials: TNBC
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd